Vaccine Info

Meningococcal Vaccines

Authored by
Last reviewed
December 29, 2022
Fact checked by
Robert Carlson, MD

Meningococcal Vaccines Overview

The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) Meningococcal Vaccine Recommendations were updated on June 23, 2022. There are two types of meningococcal vaccines licensed by the U.S. Food and Drug Administration (FDA) in the United States: Meningococcal conjugate (MenACWY) vaccines and Serogroup B meningococcal (MenB) vaccines.

The ACIP Meningococcal Vaccines Work Group meeting on October 20, 2022, led by Katherine Poehling, MD, MPH Work Group Chair, reviewed an overview and a Plan for Assessing the MenABCWY Vaccines. In the U.S., the current vaccination schedules for adolescents and young adults, as of September 2022, include a MenACWY vaccine and a separate MenB vaccine (four doses) to help achieve the broadest protection available against meningococcal disease. 

Meningitis Outbreaks

Together, five serogroups (A, B, C, W, and Y) account for 96% of all invasive meningococcal disease cases worldwide, with serogroup B accounting for most diseases in adolescents and young adolescent adults in the U.S. and Europe, reports the U.S. NIH. The WHO Africa and its partners announced on September 6, 2022, they have launched a roadmap aimed at stopping bacterial meningitis outbreaks by 2030, urging countries to implement it rapidly before the start of the meningitis season in January 2023. More than 350 million people in 24 high-risk African countries have received the MenAfriVac vaccine since 2010. 

Quadrivalent Meningococcal Conjugate (MenACWY) Vaccines

Menactra vaccine is for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in persons nine months through 55.

Menveo vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons two months through 55.

MenQuadfi vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for use in individuals two years of age and older.

Serogroup B Meningococcal (MenB) Vaccines

Trumenba vaccine is for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for individuals 10-25 years of age.

Bexsero is a vaccine to prevent invasive diseases caused by Neisseria meningitidis serogroup B. Bexsero was approved for use in 2015 for individuals 10 through 25. 

Two additional licensed meningococcal vaccines are no longer available in the United States: 1) a quadrivalent (serogroups A, C, W, and Y) meningococcal polysaccharide vaccine (MPSV4) (Menomune – A/C/Y/W-135) and 2) a combined Haemophilus influenzae type b and meningococcal serogroups C and Y conjugate vaccine (Hib-MenCY-TT) (MenHibrix).

Meningococcal Vaccine Candidates

Pfizer's investigational pentavalent meningococcal vaccine (MenABCWY) candidate is conducting a phase 3 clinical trial and could help simplify the meningococcal vaccination schedule by potentially reducing the total number of doses needed for individuals to be fully vaccinated against the five serogroups.

Meningococcal Vaccine Market Size

According to a Comprehensive Research Report published on September 7, 2022, the Meningococcal Vaccines Market may reach about U.S. $5.91 billion by 2030.

Meningococcal Vaccine News

December 28, 2022 - The U.S. FDA accepted for review the Biologics License Application for Pfizer's Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents.

September 15, 2022 - Pfizer Inc. announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. In addition, the investigational vaccine demonstrated non-inferiority to licensed vaccines for the five meningococcal serogroups that cause the most invasive meningococcal disease: serogroups A, B, C, W, and Y.

June 22, 2022 - The U.S. CDC continues collaborating with the Florida Department of Health to investigate an outbreak of meningococcal disease among men. At least 24 cases and six deaths among gay and bisexual men have been reported. In response to this outbreak, CDC is recommending gay, bisexual, and other men who have sex with men get a meningococcal vaccine (MenACWY) if they live in Florida or talk with their healthcare provider about getting vaccinated if they are traveling to Florida.

September 28, 2021 - The World Health Organization and partners announced that urgent action is needed to address meningitis while launching the first-ever global strategy to battle the disease, the Global Roadmap to Defeat Meningitis, by 2030. The new meningitis strategy aims to save more than 200,000 lives annually.

Clinical Trials

No clinical trials found